TW202342477A - 二醯基甘油激酶(DGK) α抑制劑及其用途 - Google Patents

二醯基甘油激酶(DGK) α抑制劑及其用途 Download PDF

Info

Publication number
TW202342477A
TW202342477A TW112107272A TW112107272A TW202342477A TW 202342477 A TW202342477 A TW 202342477A TW 112107272 A TW112107272 A TW 112107272A TW 112107272 A TW112107272 A TW 112107272A TW 202342477 A TW202342477 A TW 202342477A
Authority
TW
Taiwan
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
heteroaryl
compound
Prior art date
Application number
TW112107272A
Other languages
English (en)
Chinese (zh)
Inventor
陸洪福
余華星
丁曉
任峰
Original Assignee
香港商英矽智能科技知識產權有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港商英矽智能科技知識產權有限公司 filed Critical 香港商英矽智能科技知識產權有限公司
Publication of TW202342477A publication Critical patent/TW202342477A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112107272A 2022-03-01 2023-03-01 二醯基甘油激酶(DGK) α抑制劑及其用途 TW202342477A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
WOPCT/CN2022/078653 2022-03-01
CN2022078653 2022-03-01
WOPCT/CN2022/091497 2022-05-07
CN2022091497 2022-05-07
CN2022127020 2022-10-24
WOPCT/CN2022/127020 2022-10-24
WOPCT/CN2023/071857 2023-01-12
CN2023071857 2023-01-12

Publications (1)

Publication Number Publication Date
TW202342477A true TW202342477A (zh) 2023-11-01

Family

ID=87883011

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112107272A TW202342477A (zh) 2022-03-01 2023-03-01 二醯基甘油激酶(DGK) α抑制劑及其用途

Country Status (12)

Country Link
US (2) US20240051958A1 (https=)
EP (1) EP4486741A4 (https=)
JP (1) JP2025508971A (https=)
KR (1) KR20240156394A (https=)
CN (1) CN118871438A (https=)
AR (1) AR128669A1 (https=)
AU (1) AU2023227010A1 (https=)
CA (1) CA3244501A1 (https=)
IL (1) IL315015A (https=)
MX (1) MX2024010648A (https=)
TW (1) TW202342477A (https=)
WO (1) WO2023165504A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4486741A4 (en) 2022-03-01 2026-04-08 Insilico Medicine Ip Ltd Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
EP4661869A1 (en) 2023-02-06 2025-12-17 Bayer Aktiengesellschaft Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators
WO2025051110A1 (en) * 2023-09-04 2025-03-13 Insilico Medicine Ip Limited Combinations treatments of diacylglycerol kinase (dgk) alpha inhibitors and other therapies

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
EP1613625A1 (en) 2003-03-14 2006-01-11 AstraZeneca AB Novel fused triazolones and the uses thereof
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
WO2011075747A1 (en) 2009-12-18 2011-06-23 Glaxosmithkline Llc Therapeutic compounds
US10376504B2 (en) * 2015-07-29 2019-08-13 Merck, Sharp & Dohme Corp. Substituted quinolinones as PDE9 inhibitors
CN111406050B (zh) * 2018-01-17 2023-02-03 厦门宝太生物科技股份有限公司 吲哚胺2,3-双加氧酶抑制剂及其用途
KR102767739B1 (ko) 2018-06-27 2025-02-12 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물
CN112585139B (zh) 2018-06-27 2023-12-01 百时美施贵宝公司 用作t细胞激活剂的萘啶酮化合物
BR112021026687A2 (pt) 2019-07-04 2022-03-08 Lead Pharma Holding Bv Composto ou um sal farmaceuticamente aceitável do mesmo, uso do dito composto e medicamento
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
JP7629912B2 (ja) 2019-10-18 2025-02-14 リード ファーマ ホールディング ビー．ブイ． エストロゲン関連受容体アルファ（ＥＲＲα）モジュレーター
US20230064809A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CR20220236A (es) * 2019-11-28 2022-10-03 Bayer Pharma AG Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
US20230062100A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
IL294085A (en) 2019-12-19 2022-08-01 Bristol Myers Squibb Co Combinations of dgk inhibitors and checkpoint antagonists
BR112022012204A2 (pt) * 2019-12-23 2022-09-13 Bristol Myers Squibb Co Compostos de heteroarila substituída úteis como ativadores de célula t
KR20220119456A (ko) 2019-12-23 2022-08-29 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 퀴놀리노닐 피페라진 화합물
CA3162979A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
BR112022012179A2 (pt) 2019-12-23 2022-09-06 Bristol Myers Squibb Co Compostos de quinazolina substituída úteis como ativadores de célula t
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Compounds that regulate diacylglycerol kinase
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
WO2022133083A1 (en) 2020-12-16 2022-06-23 Gossamer Bio Services, Inc. Compounds useful as t cell activators
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
WO2023011456A1 (en) 2021-08-03 2023-02-09 Beigene, Ltd. Pyrazolopyridinone compounds
JP2025507915A (ja) 2022-03-01 2025-03-21 インシリコ メディスン アイピー リミティド ジアシルグリセロールキナーゼ（ＤＧＫ）α阻害剤及びその使用
EP4486741A4 (en) 2022-03-01 2026-04-08 Insilico Medicine Ip Ltd Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
WO2023165525A1 (en) 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2023165528A1 (en) 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
US20250215014A1 (en) 2022-03-31 2025-07-03 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof
CN118974049A (zh) 2022-03-31 2024-11-15 益方生物科技(上海)股份有限公司 激酶抑制剂，其制备方法和用途

Also Published As

Publication number Publication date
AU2023227010A1 (en) 2024-09-12
EP4486741A1 (en) 2025-01-08
EP4486741A4 (en) 2026-04-08
CN118871438A (zh) 2024-10-29
US20240116935A1 (en) 2024-04-11
IL315015A (en) 2024-10-01
US12077538B2 (en) 2024-09-03
AR128669A1 (es) 2024-06-05
US20240051958A1 (en) 2024-02-15
MX2024010648A (es) 2024-11-08
CA3244501A1 (en) 2023-09-07
KR20240156394A (ko) 2024-10-29
WO2023165504A1 (en) 2023-09-07
JP2025508971A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
AU2020214404B2 (en) Immunomodulators, compositions and methods thereof
TWI912127B (zh) KRas G12D抑制劑
CA2971640C (en) Cot modulators and methods of use thereof
CA3226720A1 (en) Kras g12d inhibitors and uses thereof
TW202342477A (zh) 二醯基甘油激酶(DGK) α抑制劑及其用途
TWI627174B (zh) Ｐ２ｘ７調控劑
AU2013344049A1 (en) ALK kinase inhibitors
TW202342478A (zh) 二醯基甘油激酶（ＤＧＫ）α抑制劑及其用途
TWI826535B (zh) 環狀二核苷酸類似物、其藥物組合物及應用
WO2023165525A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2023165528A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2024149389A1 (zh) 取代桥环类抑制剂及其制备方法和应用
CN120535527A (zh) 一类含氮稠环类化合物、制备方法和用途
CN121941684A (zh) Cbl-b抑制剂及其使用方法
KR20250073137A (ko) Egfr 억제제 및 그의 용도
AU2023224815A1 (en) Compound as fak inhibitor and use thereof
CN117729921A (zh) 作为pd1/pd-l1抑制剂的化合物及其方法
KR20240093606A (ko) 치환된 1H-피라졸로[4,3-c] 퀴놀린, 이의 제조 방법 및 용도
KR20230158659A (ko) Ctla-4 소분자 분해제 및 그 응용
TW202330519A (zh) 作為ｔａｍ抑制劑的吡唑并吡啶化合物
EA052540B1 (ru) Ингибиторы альфа-диацилглицеринкиназы (дгк) и способы их применения
HK40117800A (zh) 二酰基甘油激酶(DGK)α抑制剂及其用途
CN120712269A (zh) Fgfr2和fgfr3的抑制剂及其用途
HK40032239A (en) Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof
HK40032239B (en) Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof